This is a new guideline from NICE on a new treatment for MS. Obviously we won’t be prescribing this, but I thought it worth mentioning as we may see patients starting to use it.
It is an oral medication, given as short courses (eg for 2 years, it is given for just a few days in each of a couple of months). This compares to other medications, which are either daily and continuous, or injections, or IV medications given in hospital.
It will be used as a second line treatment in relapsing-remitting MS, or in rapidly evolving severe relapsing-remitting MS.